The much-awaited coronavirus vaccine is now developed, Bharat Biotech an institute of India has invented the corona vaccine and now the trials will also begin soon.
Since the time coronavirus started spreading globally, people are waiting for someone to develop covid vaccine so that everyone can get back to their normal lives. Countries like USA, Russia, China, Australia, India and more are working on the vaccine and now finally we can say that the wait is over.
Bharat Biotech collaborated with the Indian Council of Medical Research and discovered the first covid vaccine in India. The vaccine is named ‘Covaxin’ and phase 2 trials have already begun in Hyderabad. Bharat Biotech has received permission from the drug regulator to start the trials of phase across the country. The results for the same will be announced in April-May next year.
Sai Prasad Executive Director of Bharat Biotech stated that “The benchmark for the efficacy of our anti-Covid-19 vaccine is 60%. We will be conducting the largest Phase 3 trial for Covaxin, and the efficacy results should be available by early April-May, 2021″.
Further, Prasad said “The WHO, US Food and Drug Administration, and even India’s Central Drugs Standard Control Organisation approve a respiratory vaccine if it achieves 50% efficacy; for Covaxin, we aim to achieve at least 60%, but it could also be more. Chances of the vaccine being less than 50% effective are remote, as suggested by our trial results so far, which include results from animal studies”.
ALSO READ: B PRAAK DROPS DETAILS OF QISMAT 2’S SONG
The drugmaker earlier said that the vaccine is meant to prevent infection and disease in an high amount to measure the SARS-CoV-2 virus. Covaxin is a inactivated vaccine. The phase 3 trial will be tested on 26,000 volunteers from age group of 18 and above. The phase 3 clinical trials will be injected a dose of 0.5 ml. Bharat Biotech also mentioned that once the vaccine is injected it will start working on human’s immune system.
Sai Prasad mentioned that “We have begun site preparatory exercises for Phase 3; recruitment and dosage will begin in November. The trial will provide two doses each for the vaccine and placebo recipients. Site selection and recruitment depend on several factors such as attack rate, how the disease spreads locally, etc. About 2,000 subjects could be enrolled per hospital”
The trials will be held in 10 states including Delhi, Mumbai, Patna, Lucknow of India. The phase 3 trial’s expense is said to be ₹150 crores.
There is only hope that the vaccine will do its job perfectly, citizens can expect the covid vaccine to be available in a few months. Hopefully, now life can get back to normal but until than precautions should be taken and social distancing must be continued.